GSK leads pharma companies contributing to venture capital-managed Dementia Discovery Fund

22 October 2015

A new investment fund, the Dementia Discovery Fund, has been launched and managed by venture capital firm SV Life Sciences, after raising $100 million from investors throughout the industry.

The UK’s Department of Health, the charity Alzheimer’s Research UK and six pharma companies have raised $100 million to invest in early-stage, novel treatments for Alzheimer’s, Parkinson’s and other forms of dementia. The six companies are GlaxoSmithKline (LSE: GSK), Johnson & Johnson (NYSE: JNJ), Biogen (Nasdaq: BIIB), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE) and Takeda (TYO: 4502). GSK is making the biggest contribution towards the fund with $25 million, while the UK government is giving $22 million.

The stated goal of the fund, which was first announced in March, is to "deliver new drug approaches for dementia by 2025 to diagnose, intervene early and treat to modify the course and symptoms of the disease."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK